Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system

Tomohiro Yamaguchi(Yokohama City University), Takuji Okusaka(National Cancer Centre Japan), Kenji Ishido(Kitasato University), Junji Furuse(Kanagawa Prefectural Hospital Organization), Kazutoshi Tobimatsu(Kobe University), Akiyoshi Kasuga(The Cancer Institute Hospital), Nozomu Machida(Shizuoka Cancer Center), Tomohiro Nishina(Shikoku Cancer Center), Hideaki Takahashi(National Cancer Center Hospital East), Chigusa Morizane(Tokyo National Hospital), Kentaro Sudo(Chiba Cancer Center), Narikazu Boku(Tokyo Medical University)
Cancer Science
June 28, 2014
10.1111/cas.12473
Cited by 238

Related Papers

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1k
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
|The Oncologist|2010|977